Pathogenic Mechanisms of Liver Injury, Management and Current Challenges in COVID-19 Patients

Conor Lewis*

Department of Medicine, University of Texas Medical Branch, Galveston, USA

Introduction

The COVID-19 pandemic has profoundly impacted global health, with the virus causing severe respiratory symptoms in many patients, alongside a wide spectrum of multi-organ involvement. One of the critical organs affected in severe cases of COVID-19 is the liver. Hepatic injury in COVID-19 patients has emerged as a significant concern, influencing both the progression of the disease and the management of infected individuals. Early studies indicated that liver dysfunction is common among COVID-19 patients, ranging from mild elevations in liver enzymes to severe liver failure. Understanding the pathogenic mechanisms underlying liver injury, effective management strategies, and the current challenges in addressing this issue are crucial to improving patient outcomes and guiding clinical practice. Liver injury in COVID-19 patients is multifactorial, and its pathogenesis is complex. Several mechanisms have been proposed, ranging from direct viral effects to indirect damage from the body's immune response and treatment-related complications. The SARS-CoV-2 virus, which causes COVID-19, is known to primarily affect the respiratory system; however, it can also infect other tissues and organs, including the liver. The liver's susceptibility to viral infection is thought to be related to the presence of ACE2 receptors, which SARS-CoV-2 uses to enter human cells. Although ACE2 receptors are most abundant in the lungs, they are also expressed in liver cells, particularly hepatocytes and cholangiocytes. The binding of the virus to these receptors likely facilitates the direct entry of SARS-CoV-2 into liver cells, leading to viral replication within the liver and the initiation of an inflammatory response.

Description

The direct viral damage to liver cells is compounded by the body's immune response. In severe COVID-19 cases, the immune system can become hyperactivated, leading to a cytokine storm. This exaggerated immune response releases pro-inflammatory cytokines, which can cause widespread tissue damage, including in the liver. The cytokine storm is associated with endothelial injury, increased vascular permeability, and the recruitment of inflammatory cells to the site of infection, resulting in further hepatic damage. This immune-mediated injury is especially concerning because it can exacerbate the underlying liver dysfunction, leading to a vicious cycle of inflammation and injury. Additionally, liver injury in COVID-19 patients may be influenced by pre-existing conditions. Many individuals with severe COVID-19 have comorbidities such as Non-Alcoholic Fatty Liver Disease (NAFLD), chronic liver diseases (such as hepatitis B or C), or cirrhosis, which predispose them to greater liver injury. These underlying conditions can make the liver more vulnerable to both the direct effects of SARS-CoV-2 and the systemic inflammatory response triggered by the infection. Furthermore, the use of certain medications, such as antivirals, steroids, and other treatments for COVID-19, can exacerbate liver damage, either through hepatotoxicity or altering the metabolism of liver enzymes [1,2].

Address for Correspondence*: Conor Lewis, Department of Medicine, University of Texas Medical Branch, Galveston, USA, E-mail: lewisconor@gmail.com*

The management of liver injury in COVID-19 patients presents several challenges. In mild cases, liver enzyme abnormalities may be transient and resolve as the infection improves. However, in patients with severe liver dysfunction, management becomes more complex. The cornerstone of treatment for liver injury in COVID-19 remains supportive care. Since there is currently no specific antiviral therapy that directly targets the liver, the focus is on managing the systemic effects of COVID-19 while minimizing liver damage. Early identification of liver injury through routine monitoring of Liver Function Tests (LFTs) is essential. Elevated levels of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and bilirubin are indicative of liver injury, and these parameters should be regularly assessed to guide therapeutic decisions. In more severe cases, especially when liver failure is imminent, liver transplantation may be considered. However, liver transplantation in COVID-19 patients is fraught with complications. The immunosuppressive therapies required to prevent transplant rejection may increase the risk of viral reactivation or opportunistic infections, complicating patient management. Moreover, patients with advanced liver disease may have diminished immune function, further increasing their susceptibility to infections, including SARS-CoV-2 [3].

The role of medications in liver injury management also requires careful consideration. While some antiviral drugs, such as remdesivir, have shown promise in treating COVID-19, their use must be balanced against their potential for hepatotoxicity. Hepatologists must closely monitor patients receiving these therapies for any signs of liver dysfunction. Similarly, corticosteroids, commonly used to manage inflammation in COVID-19, may have mixed effects on the liver. While steroids can help modulate the immune response and reduce inflammation, their long-term use can exacerbate pre-existing liver conditions, particularly in patients with NAFLD or cirrhosis. The use of anticoagulants, which has become standard practice in severe COVID-19 cases to prevent thrombosis, can also increase the risk of bleeding complications, further complicating the clinical picture in patients with liver dysfunction. A major challenge in managing liver injury in COVID-19 patients lies in the uncertainty regarding the long-term effects of the infection. Many COVID-19 survivors have reported lingering symptoms, often referred to as "long COVID," and these can include persistent liver dysfunction. It remains unclear whether SARS-CoV-2 infection leads to permanent liver damage or if recovery from acute liver injury is possible in most patients. The long-term consequences of liver injury caused by COVID-19 are still being studied, and there is a need for extended follow-up to assess the extent of liver damage, the potential for fibrosis or cirrhosis, and the need for long-term care in affected individuals [4].

In the face of these challenges, there is a pressing need for a comprehensive approach to managing liver injury in COVID-19 patients. This includes not only improving our understanding of the pathogenic mechanisms underlying liver injury but also developing more effective therapeutic strategies. For instance, targeted therapies that modulate the immune response, inhibit viral replication, or protect liver cells from damage could offer potential benefits. Research into the long-term impact of COVID-19 on liver health is also crucial to inform future care strategies. Additionally, early identification of patients at risk of liver injury, such as those with pre-existing liver disease or other risk factors, can help guide management. More refined diagnostic tools, such as non-invasive liver biopsy alternatives, could play a crucial role in identifying patients with significant liver damage who may require more aggressive interventions. Furthermore, personalized treatment approaches that consider both the severity of COVID-19 and the individual's baseline liver health could help optimize patient outcomes [5].

Conclusion

As the global medical community continues to grapple with the COVID-19 pandemic, the liver-related complications of the disease must not be overlooked. Hepatic injury is a significant concern for many patients, and addressing the complex interplay of direct viral effects, immune-mediated damage, and medication-related toxicity requires a multidisciplinary approach. Clinicians must remain vigilant in monitoring liver function in COVID-19 patients and continue to adapt management strategies as more data becomes available. While the pathogenesis of liver injury in COVID-19 patients is still being elucidated, the integration of emerging research findings with current clinical practices will be essential in improving patient care and outcomes. The lessons learned from the COVID-19 pandemic will undoubtedly inform future approaches to managing liver disease and other multi-organ complications in infectious diseases, and it is imperative that we continue to refine our understanding and management of this complex issue.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Du, Min, Song Yang, Min Liu and Jue Liu. "COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms." *Clin Res Hepatol Gastroenterol* 46 (2022): 101793.

2. Gupta, Aakriti, Mahesh V. Madhavan, Kartik Sehgal and Nandini Nair, et al. "Extrapulmonary manifestations of COVID-19." *Nat med* 26 (2020): 1017-1032.

3. Cai, Qingxian, Deliang Huang, Hong Yu and Zhibin Zhu, et al. "COVID-19: Abnormal liver function tests." *J Hepatol* 73 (2020): 566-574.

4. Effenberger, Maria, Christoph Grander, Felix Grabherr and Andrea Griesmacher, et al. "Systemic inflammation as fuel for acute liver injury in COVID-19." *Dig Liver Dis* 53 (2021): 158-165.

5. Halim, Ceria, Audrey Fabianisa Mirza and Mutiara Indah Sari. "The association between TNF-α, IL-6, and vitamin D levels and COVID-19 severity and mortality: A systematic review and meta-analysis." *Pathog* 11 (2022): 195.